Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 28, 2008

Affitech Gains Rights to Pharmexa's Diabody Technology

  • Affitech has acquired full rights to Pharmexa’s diabody technology. Affitech had an exclusive license to diabody IP from 2007 to carry out certain nonclinical GLP-compliant studies and sublicensing deals.

    Also known as bi-specific single-chain antibodies, diabodies are recombinant antibody-like proteins. Affitech will use the technology to fuel its own pipeline as well as partnerships.